[144] Enovix Corporation Warrant SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Enovix Corporation (warrants): The filing notifies a proposed brokered sale of 1,914,466 warrants on Nasdaq with an aggregate market value of $2,641,963, scheduled approximately for 08/28/2025. The filing shows total warrants outstanding of 29,233,276, and that the warrants were acquired as dividends from the issuer on 09/24/2020 (519,853 warrants) and 07/13/2021 (1,394,613 warrants). No securities were reported sold by the holder in the past three months. Standard attestation language is included that the seller has no undisclosed material adverse information.

Positive

• Transparent disclosure of the proposed sale amount, market value, broker, and scheduled sale date
• Acquisition history provided showing the warrants were received as dividends on 09/24/2020 and 07/13/2021
• No sales reported by the holder in the past three months

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine Form 144 filing disclosing a planned brokered sale of warrants representing a modest portion of outstanding instruments.

The filing documents a proposed sale of 1,914,466 Enovix warrants with an aggregate market value of $2,641,963, to be executed through UBS Financial Services on Nasdaq on or about 08/28/2025. Acquisition details show the warrants were received as dividends in 2020 and 2021. There are no reported disposals in the prior three months. From an investor-information standpoint, this is a standard insider-related liquidity disclosure rather than an operational or financial disclosure about the issuer.

Corporate Governance Expert

TL;DR: Clean procedural disclosure; contains required seller attestation but lacks identifying filer CIK details in the provided excerpt.

The notice includes the requisite representation that the seller is unaware of undisclosed material adverse information and specifies broker and sale particulars. The excerpt does not show identifying filer CIK or contact fields filled, which are typically present on the full filing; the absence of those details in this extract limits assessment of the filer’s role or affiliation. Otherwise, the form follows standard Rule 144 reporting conventions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Warrant	UBS Financial Services Inc 1000 Harbor Blvd 3rd Floor Weehawken NJ 07086	1914466	2641963	29233276	08/28/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Warrant	09/24/2020	Dividend	Issuer			519853	09/24/2020	N/A
Warrant	07/13/2021	Dividend	Issuer			1394613	07/13/2021	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What quantity of Enovix warrants (ENVXW) does the Form 144 propose to sell?

The notice proposes the sale of 1,914,466 warrants.

What is the aggregate market value of the proposed sale in the Form 144?

The aggregate market value is reported as $2,641,963.

When is the approximate sale date listed on the Form 144 for ENVXW warrants?

The approximate date of sale is listed as 08/28/2025.

Through which broker is the proposed sale to be executed?

The broker named is UBS Financial Services Inc (1000 Harbor Blvd, Weehawken, NJ address shown).

How many Enovix warrants were outstanding according to the filing?

The filing reports 29,233,276 warrants outstanding.

How and when were the warrants being sold originally acquired?

The warrants were acquired as dividends from the issuer on 09/24/2020 (519,853) and 07/13/2021 (1,394,613).